Volume | 306,594 |
|
|||||
News | - | ||||||
Day High | 12.27 | Low High |
|||||
Day Low | 11.7601 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
KalVista Pharmaceuticals Inc | KALV | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.96 | 11.7601 | 12.27 | 12.07 | 12.01 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,057 | 306,594 | $ 11.98 | $ 3,673,169 | - | 7.21 - 16.88 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:50:29 | 3 | $ 12.05 | USD |
KalVista Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
509.21M | 42.19M | - | 0 | -92.91M | -2.20 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
KalVista Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KALV Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 12.00 | 12.92 | 11.7601 | 12.14 | 212,406 | 0.07 | 0.58% |
1 Month | 11.53 | 12.92 | 10.13 | 11.60 | 281,511 | 0.54 | 4.68% |
3 Months | 13.11 | 14.80 | 10.13 | 12.39 | 517,967 | -1.04 | -7.93% |
6 Months | 7.73 | 16.88 | 7.39 | 12.85 | 579,226 | 4.34 | 56.14% |
1 Year | 10.08 | 16.88 | 7.21 | 11.90 | 407,298 | 1.99 | 19.74% |
3 Years | 26.20 | 30.70 | 4.12 | 11.83 | 314,686 | -14.13 | -53.93% |
5 Years | 24.00 | 45.00 | 4.12 | 16.38 | 288,311 | -11.93 | -49.71% |
KalVista Pharmaceuticals Description
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. |